<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590460</url>
  </required_header>
  <id_info>
    <org_study_id>H-9938</org_study_id>
    <nct_id>NCT00590460</nct_id>
    <nct_alias>NCT00058565</nct_alias>
  </id_info>
  <brief_title>Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia</brief_title>
  <acronym>Mafia</acronym>
  <official_title>Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to discover whether children and adults with Fanconi anemia (FA)
      can be safely and effectively transplanted with Human Leukocyte Antigen (HLA) mismatched (up
      to one haplotype), HLA-matched sibling, or unrelated donor stem cells, when leukocytolytic
      monoclonal antibodies are the sole conditioning agents (patients receiving an HLA mismatched
      transplant will receive Fludarabine as part of the conditioning regimen). Three monoclonal
      antibodies (MAb) will be used in combination. Two of them, YTH 24 and YTH 54 are rat
      antibodies directed against two contiguous epitopes on the CD45 (common leucocyte) antigen.
      They have been safely administered as part of the conditioning regimen for 12 patients
      receiving allografts (HLA matched and mismatched) at this center. They produce a transient
      depletion of &gt;90% circulating leucocytes. The third MAb is Campath 1H, a humanized rat
      anti-CD52 MAb. This MAb has been widely used to treat B cell chronic lymphocytic leukemia
      (B-CLL) and more recently has been safely given at this and other centers as part of a
      sub-ablative conditioning regimen to patients with malignant disease. Because these MAb
      produce both profound immunosuppression and significant, though transient, myelodestruction
      we believe they may be useful as the sole conditioning regimen in patients with Fanconi
      anemia, in whom the use of conventional chemotherapeutic agents for conditioning produces a
      high rate of short and long term toxicity. We anticipate MAb mediated subablative
      conditioning will permit engraftment in a high percentage of these patients with little or no
      immediate or long term toxicity. Campath IH persists in vivo for several days after
      administration and so will be present over the transplant period to deplete donor T cells as
      partial graft versus host disease (GvHD) prophylaxis. Additional GvHD prophylaxis will be
      provided by administration of the medication FK506.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be
      harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by
      failure to undergo autologous reconstitution.

      For HLA Mismatched donors, harvested peripheral blood stem cells will be enriched for CD34
      cells using the Clinimacs CD34 Reagent system.

      Fludarabine will be given as 5 daily intravenous infusions. Campath-1H will be given as 3
      daily intravenous infusions and will be followed by Anti-CD45 which will be given as four
      daily intravenous infusions that will be completed two days prior to stem cell infusion.
      Diphenydramine will be administered intravenously every 4 hours during the period of the
      course of each infusion.

      Day -8 Campath 1H as per CAGT SOP Fludarabine 30 mg/m2 -7 Campath 1H as per CAGT SOP
      Fludarabine 30 mg/m2 -6 Campath 1H as per CAGT SOP Fludarabine 30 mg/m2 -5 YTH 24/54 400ug/kg
      over 6 hr Fludarabine 30 mg/m2 -4 YTH 24/54 400ug/kg over 6 hr Fludarabine 30 mg/m2 -3 YTH
      24/54 400ug/kg over 6 hr -2 YTH 24/54 400ug/kg over 6 hr -1 -0 Stem Cell Infusion

      GVHD prophylaxis will be achieved through positive selection for CD34 resulting in &gt; 3 log T
      cell depletion. Previous reports have indicated that there is a low frequency of severe
      (Grade II/IV) GvHD after haploidentical transplants if recipients receive stem cell
      populations containing &lt;5 x 10e4 CD3 positive T cells. We hope to achieve such levels with
      our CD34 enrichment protocol. However, pharmacologic prophylaxis will be added if the CD34
      selected product contains more than 5 x 10e4 CD3+ve T cells/kg recipient weight. In addition,
      Campath 1H persists in the recipient circulation through the immediate transplant period and
      will contribute anti-GVHD activity, in vivo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Donor Engraftment</measure>
    <time_frame>100 Days</time_frame>
    <description>Number of patients with engraftment of at least 65% of donor cells 100 days after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Graft Failure</measure>
    <time_frame>100 days</time_frame>
    <description>Graft failure is defined as engraftment of less than 65% of donor cells 100 days after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Treated Related Death</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with treated related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Absolute Neutrophil Count (ANC) of 500/mm3</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of days to Absolute neutrophil count (ANC) of 500/mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Platelet Count of 20,000/mm3 Without Transfusions</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of days to Platelet count of 20,000 / mm3 without transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with grade II - IV acute Graft versus Host Disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive at 1 Year Post Transplant</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients alive at 1 year post allogeneic stem cell transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Limited Chronic GVHD From Day 100 to 365</measure>
    <time_frame>365 days</time_frame>
    <description>Number of patients with limited chronic GVHD from day 100 to 365</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Extensive Chronic GVHD From Day 100 to 365</measure>
    <time_frame>365 days</time_frame>
    <description>Number of patients with extensive chronic GVHD from day 100 to 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Grade III - IV Acute GVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with Grade III-IV acute GVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Fanconi Anemia</condition>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAMPATH-1H</intervention_name>
    <description>Given intravenous on days -8, -7, and -6</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD45</intervention_name>
    <description>Given intravenous on days -5, -4, -3 and -2
dose is 400 micrograms/kg</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given intravenous on days -8, -7, -6, -5 and -4
Dose is 30 mg/m2</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell infusion</intervention_name>
    <description>Stem cells are infused on day 0</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of Fanconi Anemia or other suspected DNA breakage/chromosomal instability
        syndromes, such as dyskeratosis congenita or Nijmegen breakage syndrome of all ages are
        eligible.

        Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow
        sensitivity to mitomycin C or DEB or clinical evidence of other DNA breakage/chromosomal
        instability syndrome as determined by genetic testing or clinical diagnosis by a geneticist

        Severe aplasia anemia as evidenced by a hypocellular bone marrow and at least 1 of the 3
        criteria below: ANC &lt; 500/mm3 Hemoglobin &lt; 10 gm/dl with reticulocyte count &lt; 1% Platelet
        count &lt; 50,000/mm3

        Availability of an HLA matched or mismatched (up to one haplotype) family member who has
        been documented not to have Fanconi anemia or of an unrelated HLA matched stem cell donor.
        Fully matched is defined at 6/6 match by high resolution DR based DNA typing.

        Life expectancy greater than 6 weeks limited by diseases other than FA

        Creatinine 2X normal for age or less

        Karnofsky score 70% or more

        Exclusion Criteria:

        Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by
        echocardiogram (i.e., shortening fraction less than 25%).

        Patients with known allergy to rat serum products.

        Patients with a severe infection that on evaluation by the Principal Investigator precludes
        ablative chemotherapy or successful transplantation.

        Patients with severe personality disorder or mental illness.

        Patients with documented HIV positivity.

        Pregnant

        NOTE: Patients who would be excluded from the protocol strictly for laboratory
        abnormalities can be included at the investigator's discretion after approval by the CCGT
        Protocol Review Committee and the FDA Reviewer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Brenner, M.B., Ph.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>July 2, 2012</results_first_submitted>
  <results_first_submitted_qc>July 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2012</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Malcolm Brenner</investigator_full_name>
    <investigator_title>Professor, Director Center for Cell and Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>Fanconi Anemia</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>fludarabine</keyword>
  <keyword>campath</keyword>
  <keyword>anti-CD45</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allo Stem Cell Transplant</title>
          <description>Allogeneic Stem Cell Transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group1</title>
          <description>only one group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 5 and 9 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 10 and 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Donor Engraftment</title>
        <description>Number of patients with engraftment of at least 65% of donor cells 100 days after transplantation</description>
        <time_frame>100 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Donor Engraftment</title>
          <description>Number of patients with engraftment of at least 65% of donor cells 100 days after transplantation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Graft Failure</title>
        <description>Graft failure is defined as engraftment of less than 65% of donor cells 100 days after transplantation.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group - Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Graft Failure</title>
          <description>Graft failure is defined as engraftment of less than 65% of donor cells 100 days after transplantation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Treated Related Death</title>
        <description>Number of patients with treated related death</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allo Stem Cell Transplant</title>
            <description>Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Treated Related Death</title>
          <description>Number of patients with treated related death</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Absolute Neutrophil Count (ANC) of 500/mm3</title>
        <description>Number of days to Absolute neutrophil count (ANC) of 500/mm3</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Absolute Neutrophil Count (ANC) of 500/mm3</title>
          <description>Number of days to Absolute neutrophil count (ANC) of 500/mm3</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="14" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Platelet Count of 20,000/mm3 Without Transfusions</title>
        <description>Number of days to Platelet count of 20,000 / mm3 without transfusions</description>
        <time_frame>30 Days</time_frame>
        <population>Participants achieved a platelet count of 20,000 / mm3 without transfusions.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Platelet Count of 20,000/mm3 Without Transfusions</title>
          <description>Number of days to Platelet count of 20,000 / mm3 without transfusions</description>
          <population>Participants achieved a platelet count of 20,000 / mm3 without transfusions.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)</title>
        <description>Number of patients with grade II - IV acute Graft versus Host Disease (GVHD)</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)</title>
          <description>Number of patients with grade II - IV acute Graft versus Host Disease (GVHD)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive at 1 Year Post Transplant</title>
        <description>Number of patients alive at 1 year post allogeneic stem cell transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at 1 Year Post Transplant</title>
          <description>Number of patients alive at 1 year post allogeneic stem cell transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Limited Chronic GVHD From Day 100 to 365</title>
        <description>Number of patients with limited chronic GVHD from day 100 to 365</description>
        <time_frame>365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Limited Chronic GVHD From Day 100 to 365</title>
          <description>Number of patients with limited chronic GVHD from day 100 to 365</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Extensive Chronic GVHD From Day 100 to 365</title>
        <description>Number of patients with extensive chronic GVHD from day 100 to 365.</description>
        <time_frame>365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Extensive Chronic GVHD From Day 100 to 365</title>
          <description>Number of patients with extensive chronic GVHD from day 100 to 365.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Grade III - IV Acute GVHD</title>
        <description>Number of patients with Grade III-IV acute GVHD</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Grade III - IV Acute GVHD</title>
          <description>Number of patients with Grade III-IV acute GVHD</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group1</title>
          <description>only one group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNC hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Picorna virus sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Herpes simplex type I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Malcolm Brenner, MD</name_or_title>
      <organization>BAYLOR</organization>
      <phone>832-824-4663</phone>
      <email>mbrenner@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

